April 3, 2020
Broad Institute
415 Main Street, Cambridge, MA 02142



Click to Download the APC 2019 Program 

Plenary Speaker for APC 2019

Stuart L. Schreiber, Morris Loeb Professor of Chemistry and Chemical Biology, Harvard University, Core Institute Member, Broad Institute

Chemistry Towards Novel Mechanism-of-Action Compounds in Therapeutics Discovery




Speakers Confirmed for APC 2019

Susan Ashwell, Vice President of Chemistry, Ra Pharmaceuticals

Discovery and Development of Macrocyclic Peptides for the Treatment of Complement-Mediated Disorders


Paul Blainey,  Associate Professor of Biological Engineering, MIT and Core Faculty Member, Broad Institute of MIT and Harvard

Scalable Combinatorial Screening of Microbes


Thomas Caferro, Medicinal Chemist, Novartis

Discovery of Clinical Candidate IDH305, a Mutant IDH1 Inhibitor


Peter Cornelius, Senior Director, Translational Research, SynDevRx

SDX-7320: a Novel Polymer-Conjugated MetAP2 Inhibitor for Cancers Stimulated by Metabolic Hormones


Paul Dransfield, Principal ScientistAmgen

Discovery of AMG 986, a Potent, Selective and Orally Bioavailable APJ Agonist for theTreatment of Heart Disease



Andrew Fensome, Associate Research Fellow, Pfizer

Inhibition of Autoimmune Pathways with Dual Inhibition of JAK1 and TYK2: Discovery of PF-06700841


Aarti Kawatkar, Sr. Scientist, Chemical Biology, Chemistry Innovation Center, Discovery Science, AstraZeneca

Shining The Light on Small Molecule Inhibitors of MCT4


Ryan Moslin, Senior Research Scientist, Bristol Myers-Squibb

Inhibition of TYK2 via the Pseudokinase: The Discovery of BMS-986165


Woody Sherman, Chief Scientific Officer, Silicon Therapeutics

Physics-Based Drug Discovery for Tackling Challenge Targets


Dehua Pei, Kimberly Professor, Department of Chemistry and Biochemistry, The Ohio State University

Targeting Intracellular Protein-Protein Interactions with Macrocyclic Peptides


Wes Trotter, Director, Medicinal Chemistry, Merck

Novel STING Agonists for Immuno-oncology


Adrian Whitty, Associate Professor, Departments of Chemistry and Pharmacology and Experimental Therapeutics, Boston University

Synthetic Macrocycles for the Inhibition of Challenging PPI Targets


Proposed Sessions for 2019:

Session I:  Tumor Metabolism and Immunometabolism

Session II: Recent Success Stories

Session III: Strategies for Drugging Difficult Targets


Join our LinkedIn Group


Session I:  Tumor Metabolism and Immunometabolism

Session II: Recent Success Stories

Session III: Strategies for Drugging Difficult Targets


Click here to register for the APC 2019 conference online.

APC 2019 will take place April 5, 2019 at:

Broad Institute, Cambridge, MA


The Boston Society

The Boston Society (R) is an internationally-recognized NON-PROFIT organization dedicated to bringing the best scientific ideas to industrial practice through focused, timely workshops and conferences. 501(c)3


Sign Up Today!

Privacy Policy